0 NASDAQ Companies - January 7, 2024Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year […]Read More
0 NASDAQ Companies - January 7, 2024Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceTetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data […]Read More
0 NASDAQ Companies - January 7, 2024Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaInvestigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients […]Read More
0 NYSE Companies - January 7, 2024QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekanntKapitalrückzahlung durch synthetischen Aktienrückkauf // Rückzahlung von bis zu $300 Mio. – von Aktionärinnen und Aktionären im Jahr 2023 genehmigter […]Read More
0 NYSE Companies - January 7, 2024QIAGEN announces plans to return approximately $300 million to shareholdersVenlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a […]Read More
0 NASDAQ Companies - January 7, 2024Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms GuidanceCARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today […]Read More
0 NASDAQ Companies - January 7, 2024Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024— Tim Kelly to lead Caribou’s technical operations strategy and execution — — CB-010 ANTLER Phase 1 trial initial dose […]Read More
0 NASDAQ Companies - January 7, 2024Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesPreliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue […]Read More
0 NASDAQ Companies - January 7, 2024RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 GuidanceALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality […]Read More
0 NASDAQ Companies - January 7, 2024Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics WorkflowMARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that […]Read More